Levamlodipine/valsartan - Ahn-Gook Pharmaceuticals

Drug Profile

Levamlodipine/valsartan - Ahn-Gook Pharmaceuticals

Alternative Names: AGSAV-301; S-amlodipine/valsartan; Valsartan/levamlodipine - Ahn-Gook Pharmaceuticals; Valsartan/S-amlodipine

Latest Information Update: 03 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ahn-Gook Pharmaceutical
  • Class Antihypertensives; Branched-chain amino acids; Dihydropyridines; Nicotinic-acids; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hypertension

Most Recent Events

  • 03 Mar 2016 No development reported - Phase-I for Hypertension (In volunteers) in South Korea (PO)
  • 31 Oct 2013 Pharmacokinetics and adverse event data from a phase I trial in Healthy volunteers released by Ahn-Gook Pharmaceutical
  • 21 Feb 2012 Phase-I clinical trials in Hypertension (in volunteers) in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top